Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma

Open access
Chen, Yuyan, Zhu, Zhengyi, Wu, Xingyu, Li, Hui, Guan, Wenxian, Ren, Haozhen · 2024 · Cell Death Discovery

Abstract

Currently, there is still a lack of novel and effective drug targets to improve the prognosis of hepatocellular carcinoma (HCC). Additionally, the role of CHEK2 in HCC has not been reported yet. The eQTLgen database and two HCC Genome-Wide Association Study (GWAS) datasets (ieu-b-4953, ICD10 C22.0) were used to find the drug target: CHEK2. Next, Colony, Edu, β-gal, and cell cycle analysis were facilitated to evaluate the role of CHEK2 knockout in HCC. In addition, Nultin-3 was added to evaluate the apoptosis of TP53-mutated HCC cells with CHEK2 knockout. Furthermore, MitoSox, electron microscopy, mitochondrial ATP, and NADH+/NADH levels were assessed in the CHEK2 knockout HCC cells with or without Metformin. Finally, cell-derived tumor xenograft was used to evaluate the role of CHEK2 knockout in vivo. We initially identified a potential drug target, CHEK2, through GWAS data analysis. Furthermore, we observed a significant upregulation of CHEK2 expression in HCC, which was found to be correlated with a poor prognosis. Subsequently, the results indicated that knocking out CHEK2 selectively affects the proliferation, cell cycle, senescence, and apoptosis of TP53-mutant HCC cells. Additionally, the introduction of Nultin-3 further intensified the functional impact on TP53-mutant cells. Then ClusterProfiler results showed high CHEK2 and TP53 mutation group was positively enriched in the mitochondrial ATP pathway. Then we used MitoSox, electron microscopy, mitochondrial ATP, and NADH + /NADH assay and found knockout of CHECK could induce the ATP pathway to inhibit the growth of HCC. Our research introduces a novel drug target for TP53-mutant HCC cells via mitochondrial ATP, addressing the limitation of Nultin-3 as a standalone treatment that does not induce tumor cell death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41420-023-01777-4

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CHEK2 could be a potential drug target for HCC. A The workflow of identifying drug target genes. B Expression of several drug target genes in several HCC datasets. C The level of CHEK2 in the normal and HCC tissues. D The serum level of CHEK2 in the healthy donors and HCC samples. E The correlations between serum CHEK2 level and HCC CHEK2 level in 20 HCC samples. F–H KM analysis of low and high CHEK2 groups in the TCGA, ICGC, and GAO et al. databases. I The CHEK2 and Ki67 levels of IHC in the normal (n = 20) and HCC groups (n = 20). J The correlations between CHEK2 level and Ki67 level in 20 HCC samples.
Fig. 1 CHEK2 could be a potential drug target for HCC. A The workflow of identifying drug target genes. B Expression of several drug target genes in several HCC datasets. C The level of CHEK2 in the normal and HCC tissues. D The serum level of CHEK2 in the healthy donors and HCC samples. E The correlations between serum CHEK2 level and HCC CHEK2 level in 20 HCC samples. F–H KM analysis of low and high CHEK2 groups in the TCGA, ICGC, and GAO et al. databases. I The CHEK2 and Ki67 levels of IHC in the normal (n = 20) and HCC groups (n = 20). J The correlations between CHEK2 level and Ki67 level in 20 HCC samples.CC BY · PubMed Central
Fig. 2 Knockout of CHEK2 selectively induces proliferation arrest, cell cycle blockade, and senescence in HCC cells with TP53 mutation. A–C Single-gene GSEA of low and high CHEK2 groups in the TCGA, ICGC, and GAO et al. databases. D–G Colony, Edu, cell cycle and β-gal staining of control, sgCHEK21# and sgCHEK22# groups in LM3, Huh7, and hepG2 cell lines (n = 3). H–K Western blot results of control, sgCHEK21# and sgCHEK22# groups in LM3, Huh7, and hepG2 cell lines.
Fig. 2 Knockout of CHEK2 selectively induces proliferation arrest, cell cycle blockade, and senescence in HCC cells with TP53 mutation. A–C Single-gene GSEA of low and high CHEK2 groups in the TCGA, ICGC, and GAO et al. databases. D–G Colony, Edu, cell cycle and β-gal staining of control, sgCHEK21# and sgCHEK22# groups in LM3, Huh7, and hepG2 cell lines (n = 3). H–K Western blot results of control, sgCHEK21# and sgCHEK22# groups in LM3, Huh7, and hepG2 cell lines.CC BY · PubMed Central
Fig. 3 Combining Nultin-3 further induces cell cycle arrest and inhibits growth in CHEK2-inhibited HCC cells with TP53 mutation. A Expression of CHEK2 between the TP53 wild and mutation groups in the TCGA, ICGC, and GAO et al. databases. B Landscape of genomic mutations and CNV data between the low CHEK2 and high CHEK2 groups in HCC. C–E KM analysis of high CHEK2/TP53 mutation, low CHEK2/TP53 wild, and mixed groups in the TCGA, ICGC, and GAO et al. databases. F–I Colony, Edu, cell cycle and β-gal staining of control, Nultin-3, and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines (n = 3). J, K Western blot results of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines.
Fig. 3 Combining Nultin-3 further induces cell cycle arrest and inhibits growth in CHEK2-inhibited HCC cells with TP53 mutation. A Expression of CHEK2 between the TP53 wild and mutation groups in the TCGA, ICGC, and GAO et al. databases. B Landscape of genomic mutations and CNV data between the low CHEK2 and high CHEK2 groups in HCC. C–E KM analysis of high CHEK2/TP53 mutation, low CHEK2/TP53 wild, and mixed groups in the TCGA, ICGC, and GAO et al. databases. F–I Colony, Edu, cell cycle and β-gal staining of control, Nultin-3, and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines (n = 3). J, K Western blot results of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines.CC BY · PubMed Central
Fig. 4 Knockout of CHEK2 triggers apoptosis in Nultin-3-treated HCC cells. A Apoptosis analysis of control and sgCHEK21# groups with 0, 10, 20 μM Nutlin-3 in LM3, Huh7 cell lines (n = 3). B Caspase-3 staining of control and sgCHEK21# groups with 0, 10, 20 μM Nutlin-3 in LM3, Huh7 cell lines (n = 3). C Western blot results of control and sgCHEK21# groups with 0, 10, 20 μM Nutlin-3 in LM3, Huh7 cell lines.
Fig. 4 Knockout of CHEK2 triggers apoptosis in Nultin-3-treated HCC cells. A Apoptosis analysis of control and sgCHEK21# groups with 0, 10, 20 μM Nutlin-3 in LM3, Huh7 cell lines (n = 3). B Caspase-3 staining of control and sgCHEK21# groups with 0, 10, 20 μM Nutlin-3 in LM3, Huh7 cell lines (n = 3). C Western blot results of control and sgCHEK21# groups with 0, 10, 20 μM Nutlin-3 in LM3, Huh7 cell lines.CC BY · PubMed Central
Fig. 5 Combining Nultin-3 and knockout of CHEK2 exacerbates the loss of mitochondrial ATP in HCC. A ClusterProfiler results of high CHEK2/TP53 mutation, low CHEK2/TP53 wild, and mixed groups in the TCGA, ICGC, and GAO et al. databases. B–E ATP level and NADH+/NADH ratio of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines. F Western blot results of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines. G–L transmission electron microscopy, JC1 and MitoSox level of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines (n = 3).
Fig. 5 Combining Nultin-3 and knockout of CHEK2 exacerbates the loss of mitochondrial ATP in HCC. A ClusterProfiler results of high CHEK2/TP53 mutation, low CHEK2/TP53 wild, and mixed groups in the TCGA, ICGC, and GAO et al. databases. B–E ATP level and NADH+/NADH ratio of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines. F Western blot results of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines. G–L transmission electron microscopy, JC1 and MitoSox level of control, sgCHEK21# and sgCHEK21# + Nultin-3 groups in LM3, Huh7 cell lines (n = 3).CC BY · PubMed Central
Fig. 6 Combining Nultin-3 and knockout of CHEK2 could influence several biological processes of HCC via mitochondrial ATP. A–D β-gal staining, colony, Edu and cell cycle of control, sgCHEK21# + Nultin-3 and sgCHEK21# + Nultin-3 + Metformin groups in LM3, Huh7 cell lines (n = 3). E–G Western blot results and apoptosis assays of control, sgCHEK21# + Nultin-3 and sgCHEK21# + Nultin-3 + Metformin groups in LM3, Huh7 cell lines. H–Q ATP level, NADH+/NADH ratio, transmission electron microscopy, JC1 and MitoSox level of control, sgCHEK21# + Nultin-3 and sgCHEK21# + Nultin-3 + Metformin groups in LM3, Huh7 cell lines (n = 3).
Fig. 6 Combining Nultin-3 and knockout of CHEK2 could influence several biological processes of HCC via mitochondrial ATP. A–D β-gal staining, colony, Edu and cell cycle of control, sgCHEK21# + Nultin-3 and sgCHEK21# + Nultin-3 + Metformin groups in LM3, Huh7 cell lines (n = 3). E–G Western blot results and apoptosis assays of control, sgCHEK21# + Nultin-3 and sgCHEK21# + Nultin-3 + Metformin groups in LM3, Huh7 cell lines. H–Q ATP level, NADH+/NADH ratio, transmission electron microscopy, JC1 and MitoSox level of control, sgCHEK21# + Nultin-3 and sgCHEK21# + Nultin-3 + Metformin groups in LM3, Huh7 cell lines (n = 3).CC BY · PubMed Central
Fig. 7 Inhibition of CHEK2 suppresses HCC proliferation in vivo. A Construction of CDTX model for HCC between the control, sgCHEK21# and sgCHEK21# + Nultin-3 groups (n = 5). B IHC results of CDTX model for HCC between the control, sgCHEK21# and sgCHEK21# + Nultin-3 groups (n = 5). C IHC results of TP53 mutation and TP53 wild HCC slices.
Fig. 7 Inhibition of CHEK2 suppresses HCC proliferation in vivo. A Construction of CDTX model for HCC between the control, sgCHEK21# and sgCHEK21# + Nultin-3 groups (n = 5). B IHC results of CDTX model for HCC between the control, sgCHEK21# and sgCHEK21# + Nultin-3 groups (n = 5). C IHC results of TP53 mutation and TP53 wild HCC slices.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 6

Metadata

Authors
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H.
Affiliations
Nanjing Drum Tower Hospital (CN)
Corresponding author
  • Li, Hui
  • Guan, Wenxian
  • Ren, Haozhen
Venue
Cell Death Discovery
Published
2024-01-19
Volume
10
Issue
1
Pages
37-37
ISSN
2058-7716 (ISSN-L)
OpenAlex
W4391022989
Cited by
6
References
54
Citations by year
2026: 2 · 2025: 3 · 2024: 1
FWCI
1.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death Discovery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82270646)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
CHEK2, hepatocellular carcinoma, TP53 mutation, therapeutic target, apoptosis, cellular senescence, cell cycle, metformin, tumor xenografts, prognosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41420-023-01777-4
The paper
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024). CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma. Cell Death Discovery. https://doi.org/10.1038/s41420-023-01777-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.